Sulggi A Lee1, Sushama Telwatte1,2, Hiroyu Hatano1, Angela D M Kashuba3, Mackenzie L Cottrell3, Rebecca Hoh1, Teri J Liegler1, Sophie Stephenson1, Ma Somsouk4, Peter W Hunt5, Steven G Deeks1, Steven Yukl1,2, Radojka M Savic6. 1. Division of Infectious Diseases, HIV, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA. 2. San Francisco VA Medical Center (SFVAMC), San Francisco, CA. 3. Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Eschelman School of Pharmacy, Raleigh, NC. 4. Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA. 5. Division of Experimental Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA; and. 6. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA.
Abstract
BACKGROUND: Most HIV-infected cells during antiretroviral therapy (ART) persist in lymphoid tissues. Studies disagree on whether suboptimal tissue ART concentrations contribute to ongoing HIV replication during viral suppression. METHODS: We performed a cross-sectional study in virally-suppressed HIV+ participants measuring lymphoid tissue ART [darunavir (DRV), atazanavir (ATV), and raltegravir (RAL)] concentrations by LC-MS/MS assay. Tissue and plasma ART concentrations were used to estimate TPRs and drug-specific tissue:inhibitory concentration ratios (TICs). HIV DNA and sequentially produced HIV RNA transcripts were quantified from rectal biopsies using droplet digital PCR (ddPCR) assays. RESULTS: Tissue samples were collected in duplicate from 19 participants: 38 rectal, 8 ileal (4 RAL, 2 DRV, 2 ATV), and 6 lymph node (4 RAL, 2 DRV) samples. Overall, median TICs were higher for RAL than DRV or ATV (both P = 0.006). Median TICs were lower in lymph nodes vs. ileum (0.49 vs. 143, P = 0.028) or rectum (33, P = 0.019), and all ART levels were below target concentrations. Higher rectal TICs were associated with lower HIV RNA transcripts (read-through, long LTR, and Nef, P all < 0.026) and a lower long LTR RNA/long LTR DNA ratio (P = 0.021). CONCLUSIONS: We observed higher tissue ART concentrations in ileum and rectum compared with lymph nodes. We observed higher HIV transcription in participants with lower rectal ART concentrations. These findings add to the limited data supporting the idea that viral transcription may be influenced by ART concentrations in lymphoid tissues. Further exploration of tissue pharmacokinetics is needed in future HIV eradication strategies.
BACKGROUND: Most HIV-infected cells during antiretroviral therapy (ART) persist in lymphoid tissues. Studies disagree on whether suboptimal tissue ART concentrations contribute to ongoing HIV replication during viral suppression. METHODS: We performed a cross-sectional study in virally-suppressed HIV+ participants measuring lymphoid tissue ART [darunavir (DRV), atazanavir (ATV), and raltegravir (RAL)] concentrations by LC-MS/MS assay. Tissue and plasma ART concentrations were used to estimate TPRs and drug-specific tissue:inhibitory concentration ratios (TICs). HIV DNA and sequentially produced HIV RNA transcripts were quantified from rectal biopsies using droplet digital PCR (ddPCR) assays. RESULTS: Tissue samples were collected in duplicate from 19 participants: 38 rectal, 8 ileal (4 RAL, 2 DRV, 2 ATV), and 6 lymph node (4 RAL, 2 DRV) samples. Overall, median TICs were higher for RAL than DRV or ATV (both P = 0.006). Median TICs were lower in lymph nodes vs. ileum (0.49 vs. 143, P = 0.028) or rectum (33, P = 0.019), and all ART levels were below target concentrations. Higher rectal TICs were associated with lower HIV RNA transcripts (read-through, long LTR, and Nef, P all < 0.026) and a lower long LTR RNA/long LTR DNA ratio (P = 0.021). CONCLUSIONS: We observed higher tissue ART concentrations in ileum and rectum compared with lymph nodes. We observed higher HIV transcription in participants with lower rectal ART concentrations. These findings add to the limited data supporting the idea that viral transcription may be influenced by ART concentrations in lymphoid tissues. Further exploration of tissue pharmacokinetics is needed in future HIV eradication strategies.
Authors: Johan W Mouton; Ursula Theuretzbacher; William A Craig; Paul M Tulkens; Hartmut Derendorf; Otto Cars Journal: J Antimicrob Chemother Date: 2007-12-06 Impact factor: 5.790
Authors: Steven A Yukl; Philipp Kaiser; Peggy Kim; Sushama Telwatte; Sunil K Joshi; Mai Vu; Harry Lampiris; Joseph K Wong Journal: Sci Transl Med Date: 2018-02-28 Impact factor: 17.956
Authors: David E Skarda; Jodie H Taylor; Jeffrey G Chipman; Matthew Larson; Jason V Baker; Timothy W Schacker; Gregory J Beilman Journal: Surg Infect (Larchmt) Date: 2007-04 Impact factor: 2.150
Authors: Timothy W Schacker; Phuong L Nguyen; Gregory J Beilman; Steven Wolinsky; Matthew Larson; Cavan Reilly; Ashley T Haase Journal: J Clin Invest Date: 2002-10 Impact factor: 14.808
Authors: Mary F Kearney; Jonathan Spindler; Wei Shao; Sloane Yu; Elizabeth M Anderson; Angeline O'Shea; Catherine Rehm; Carry Poethke; Nicholas Kovacs; John W Mellors; John M Coffin; Frank Maldarelli Journal: PLoS Pathog Date: 2014-03-20 Impact factor: 6.823
Authors: Claire Deleage; Stephen W Wietgrefe; Gregory Del Prete; David R Morcock; Xing Pei Hao; Michael Piatak; Julian Bess; Jodi L Anderson; Katherine E Perkey; Cavan Reilly; Joseph M McCune; Ashley T Haase; Jeffrey D Lifson; Timothy W Schacker; Jacob D Estes Journal: Pathog Immun Date: 2016
Authors: Elias P Rosen; Claire Deleage; Nicole White; Craig Sykes; Catherine Brands; Lourdes Adamson; Paul Luciw; Jacob D Estes; Angela D M Kashuba Journal: J Int AIDS Soc Date: 2022-04 Impact factor: 6.707